← All trials
NCT05437224
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 18, 2018
- Primary completion
- Jan 9, 2022
- Completion date
- Feb 6, 2022
- First posted
- Jun 29, 2022
- Last posted
- Jun 29, 2022
- Enrollment
- 80
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Nanjing Medical UniversityCollaborator
- Qingdao UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Jiao Tong UniversityStudy chair
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.